An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo

Dong Wan Seo, W. Carl Saxinger, Liliana Guedez, Anna Rita Cantelmo, Adriana Albini, William G. Stetler-Stevenson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tissue inhibitor of metalloproteinases-2 (TIMP-2) inhibits angiogenesis by several mechanisms involving either MMP inhibition or direct endothelial cell binding. The primary aim of this study was to identify the TIMP-2 region involved in binding to the previously identified receptor integrin α3β1, and to determine whether synthetic peptides derived from this region retained angio-inhibitory and tumor suppressor activity. We demonstrated that the N-terminal domain of TIMP-2 (N-TIMP-2) binds to α3β1 and inhibits vascular endothelial growth factor-stimulated endothelial cell growth in vitro, suggesting that both the α3β1-binding domain and the growth suppressor activity of TIMP-2 localize to the N-terminal domain. Using a peptide array approach we identify a 24 amino acid region of TIMP-2 primary sequence, consisting of residues Ile43-Ala66, which shows α3β1- binding activity. Subsequently we demonstrate that synthetic peptides from this region compete for TIMP-2 binding to α3β1 and suppress endothelial growth in vitro. We define a minimal peptide sequence (peptide 8-9) that possesses both angio-inhibitory and, using a murine xenograft model of Kaposi's sarcoma, anti-tumorigenic activity in vivo. Thus, both the α3β1- binding and the angio-inhibitory activities co-localize to a solvent exposed, flexible region in the TIMP-2 primary sequence that is unique in amino acid sequence compared with other members of the TIMP family. Furthermore, comparison of the TIMP-2 and TIMP-1 protein 3-D structures in this region also identified unique structural differences. Our findings demonstrate that the integrin binding, tumor growth suppressor and in vivo angio-inhibitory activities of TIMP-2 are intimately associated within a unique sequence/structural loop (B-C loop).

Original languageEnglish
Pages (from-to)1840-1848
Number of pages9
JournalPeptides
Volume32
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Tissue Inhibitor of Metalloproteinase-2
Integrins
Peptides
Endothelial cells
Growth
Tumors
Endothelial Cells
Tissue Inhibitor of Metalloproteinases
Amino Acids
Tissue Inhibitor of Metalloproteinase-1
Kaposi's Sarcoma
Cell growth
Matrix Metalloproteinases
Heterografts
Vascular Endothelial Growth Factor A
Amino Acid Sequence
Neoplasms

Keywords

  • Angiogenesis
  • Angiogenesis inhibitors
  • Kaposi's sarcoma
  • Peptide inhibitors
  • Tissue inhibitor of metalloproteinases-2 (TIMP-2)

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. / Seo, Dong Wan; Saxinger, W. Carl; Guedez, Liliana; Cantelmo, Anna Rita; Albini, Adriana; Stetler-Stevenson, William G.

In: Peptides, Vol. 32, No. 9, 09.2011, p. 1840-1848.

Research output: Contribution to journalArticle

Seo, Dong Wan ; Saxinger, W. Carl ; Guedez, Liliana ; Cantelmo, Anna Rita ; Albini, Adriana ; Stetler-Stevenson, William G. / An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. In: Peptides. 2011 ; Vol. 32, No. 9. pp. 1840-1848.
@article{ae71d52944e941349cf69c4ff3f0c191,
title = "An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo",
abstract = "Tissue inhibitor of metalloproteinases-2 (TIMP-2) inhibits angiogenesis by several mechanisms involving either MMP inhibition or direct endothelial cell binding. The primary aim of this study was to identify the TIMP-2 region involved in binding to the previously identified receptor integrin α3β1, and to determine whether synthetic peptides derived from this region retained angio-inhibitory and tumor suppressor activity. We demonstrated that the N-terminal domain of TIMP-2 (N-TIMP-2) binds to α3β1 and inhibits vascular endothelial growth factor-stimulated endothelial cell growth in vitro, suggesting that both the α3β1-binding domain and the growth suppressor activity of TIMP-2 localize to the N-terminal domain. Using a peptide array approach we identify a 24 amino acid region of TIMP-2 primary sequence, consisting of residues Ile43-Ala66, which shows α3β1- binding activity. Subsequently we demonstrate that synthetic peptides from this region compete for TIMP-2 binding to α3β1 and suppress endothelial growth in vitro. We define a minimal peptide sequence (peptide 8-9) that possesses both angio-inhibitory and, using a murine xenograft model of Kaposi's sarcoma, anti-tumorigenic activity in vivo. Thus, both the α3β1- binding and the angio-inhibitory activities co-localize to a solvent exposed, flexible region in the TIMP-2 primary sequence that is unique in amino acid sequence compared with other members of the TIMP family. Furthermore, comparison of the TIMP-2 and TIMP-1 protein 3-D structures in this region also identified unique structural differences. Our findings demonstrate that the integrin binding, tumor growth suppressor and in vivo angio-inhibitory activities of TIMP-2 are intimately associated within a unique sequence/structural loop (B-C loop).",
keywords = "Angiogenesis, Angiogenesis inhibitors, Kaposi's sarcoma, Peptide inhibitors, Tissue inhibitor of metalloproteinases-2 (TIMP-2)",
author = "Seo, {Dong Wan} and Saxinger, {W. Carl} and Liliana Guedez and Cantelmo, {Anna Rita} and Adriana Albini and Stetler-Stevenson, {William G.}",
year = "2011",
month = "9",
doi = "10.1016/j.peptides.2011.08.010",
language = "English",
volume = "32",
pages = "1840--1848",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo

AU - Seo, Dong Wan

AU - Saxinger, W. Carl

AU - Guedez, Liliana

AU - Cantelmo, Anna Rita

AU - Albini, Adriana

AU - Stetler-Stevenson, William G.

PY - 2011/9

Y1 - 2011/9

N2 - Tissue inhibitor of metalloproteinases-2 (TIMP-2) inhibits angiogenesis by several mechanisms involving either MMP inhibition or direct endothelial cell binding. The primary aim of this study was to identify the TIMP-2 region involved in binding to the previously identified receptor integrin α3β1, and to determine whether synthetic peptides derived from this region retained angio-inhibitory and tumor suppressor activity. We demonstrated that the N-terminal domain of TIMP-2 (N-TIMP-2) binds to α3β1 and inhibits vascular endothelial growth factor-stimulated endothelial cell growth in vitro, suggesting that both the α3β1-binding domain and the growth suppressor activity of TIMP-2 localize to the N-terminal domain. Using a peptide array approach we identify a 24 amino acid region of TIMP-2 primary sequence, consisting of residues Ile43-Ala66, which shows α3β1- binding activity. Subsequently we demonstrate that synthetic peptides from this region compete for TIMP-2 binding to α3β1 and suppress endothelial growth in vitro. We define a minimal peptide sequence (peptide 8-9) that possesses both angio-inhibitory and, using a murine xenograft model of Kaposi's sarcoma, anti-tumorigenic activity in vivo. Thus, both the α3β1- binding and the angio-inhibitory activities co-localize to a solvent exposed, flexible region in the TIMP-2 primary sequence that is unique in amino acid sequence compared with other members of the TIMP family. Furthermore, comparison of the TIMP-2 and TIMP-1 protein 3-D structures in this region also identified unique structural differences. Our findings demonstrate that the integrin binding, tumor growth suppressor and in vivo angio-inhibitory activities of TIMP-2 are intimately associated within a unique sequence/structural loop (B-C loop).

AB - Tissue inhibitor of metalloproteinases-2 (TIMP-2) inhibits angiogenesis by several mechanisms involving either MMP inhibition or direct endothelial cell binding. The primary aim of this study was to identify the TIMP-2 region involved in binding to the previously identified receptor integrin α3β1, and to determine whether synthetic peptides derived from this region retained angio-inhibitory and tumor suppressor activity. We demonstrated that the N-terminal domain of TIMP-2 (N-TIMP-2) binds to α3β1 and inhibits vascular endothelial growth factor-stimulated endothelial cell growth in vitro, suggesting that both the α3β1-binding domain and the growth suppressor activity of TIMP-2 localize to the N-terminal domain. Using a peptide array approach we identify a 24 amino acid region of TIMP-2 primary sequence, consisting of residues Ile43-Ala66, which shows α3β1- binding activity. Subsequently we demonstrate that synthetic peptides from this region compete for TIMP-2 binding to α3β1 and suppress endothelial growth in vitro. We define a minimal peptide sequence (peptide 8-9) that possesses both angio-inhibitory and, using a murine xenograft model of Kaposi's sarcoma, anti-tumorigenic activity in vivo. Thus, both the α3β1- binding and the angio-inhibitory activities co-localize to a solvent exposed, flexible region in the TIMP-2 primary sequence that is unique in amino acid sequence compared with other members of the TIMP family. Furthermore, comparison of the TIMP-2 and TIMP-1 protein 3-D structures in this region also identified unique structural differences. Our findings demonstrate that the integrin binding, tumor growth suppressor and in vivo angio-inhibitory activities of TIMP-2 are intimately associated within a unique sequence/structural loop (B-C loop).

KW - Angiogenesis

KW - Angiogenesis inhibitors

KW - Kaposi's sarcoma

KW - Peptide inhibitors

KW - Tissue inhibitor of metalloproteinases-2 (TIMP-2)

UR - http://www.scopus.com/inward/record.url?scp=80052730897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052730897&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2011.08.010

DO - 10.1016/j.peptides.2011.08.010

M3 - Article

C2 - 21871510

AN - SCOPUS:80052730897

VL - 32

SP - 1840

EP - 1848

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 9

ER -